




Searching News Database: Taxol
HSMN NewsFeed - 17 Oct 2019
World-Renowned Cancer Leader Brian Leyland-Jones Named Chairman of NED Biosystems' Scientific Advisory Board
World-Renowned Cancer Leader Brian Leyland-Jones Named Chairman of NED Biosystems' Scientific Advisory Board
HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
HSMN NewsFeed - 11 Sep 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
HSMN NewsFeed - 13 Jan 2014
A.P. Pharma Announces Appointment of New Directors and Effective Date of Name Change and Reverse Stock Split
A.P. Pharma Announces Appointment of New Directors and Effective Date of Name Change and Reverse Stock Split
HSMN NewsFeed - 7 Jan 2014
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
HSMN NewsFeed - 2 Oct 2012
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
HSMN NewsFeed - 25 Apr 2012
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed - 26 Jan 2010
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
HSMN NewsFeed - 7 Jan 2010
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
HSMN NewsFeed - 14 Apr 2009
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
HSMN NewsFeed - 24 Feb 2009
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
HSMN NewsFeed - 14 Jul 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
HSMN NewsFeed - 5 May 2008
European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
HSMN NewsFeed - 4 Mar 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
HSMN NewsFeed - 22 Jan 2008
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
HSMN NewsFeed - 24 Sep 2007
Phase 3 Pivotal Trial of TOCOSOL(R) Paclitaxel Does Not Meet Primary Endpoint
Phase 3 Pivotal Trial of TOCOSOL(R) Paclitaxel Does Not Meet Primary Endpoint
HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
HSMN NewsFeed - 6 Jun 2007
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
HSMN NewsFeed - 1 Jun 2006
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
HSMN NewsFeed - 15 May 2006
EntreMed Initiates Combination Phase 2 Clinical Trial With Panzem(R) NCD in Carcinoid Cancer
EntreMed Initiates Combination Phase 2 Clinical Trial With Panzem(R) NCD in Carcinoid Cancer
Additional items found! 146

Members Archive contains
146 additional stories matching:
Taxol
(Password required)
Taxol
(Password required)